ATM and cancer: It will be of therapeutic interest to investigate whether small molecules that restore wild-type function to mutant p53 (e.g., CP-31398 and PRIMA-1) [49,50] can restore the TRF2-ATM-p53 positive feedback regulation in cancers with p53 mutations.